Adial Pharmaceuticals, Inc. Aktie News

GLEN ALLEN, Va., 25. Aug. 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) ("Adial" oder das "Unternehmen") gab heute bekannt, dass das Vergütungskomitee des Unternehmens eine neue Mitarbeiteraktienoption zum Kauf von 307.814 Stammaktien als Anreiz dafür gewährt hat, dass diese Person Mitarbeiter des Unternehmens wird.

Abgeschlossen: Übernahme von Azora Therapeutics, wodurch AT177, ein vollsynthetischer, oral einzunehmender, kolonzielgerichteter Aryl‑hydrokarbon‑Rezeptor („Ahr“) Agonist in Entwicklung für Colitis ulcerosa, in die Pipeline aufgenommen wurde

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options ...

- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027

GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.

New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach

Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatments inadequately address patient outcomes Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatme...

Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug produc...